Table 2. Patient Demographics.
| Characteristics (n=34) | |
|---|---|
| Age (years) | |
| Median | 62 |
| Range | 27-78 |
| Gender, n (%) | |
| Men | 18 (53%) |
| Women | 16 (47%) |
| Histologies, n (%) | |
| Adenocarcinoma | 26 (76%) |
| Squamous cell | 3 (9%) |
| Mucinous adenocarcinoma | 2 (6%) |
| Poorly differentiated carcinoma | 2 (6%) |
| Sarcomatoid carcinoma | 1 (3%) |
| No. of prior systemic therapies, n (%) | |
| Median | 4 |
| Range | 1-8 |
| Prior bevacizumab, n (%) | 11 (32%) |
| Prior EGFR inhibitors, n (%) | 13 (38%) |
| EGFR mutations, n (%) | |
| Positive | 3 (9%) |
| Negative | 16 (47%) |
| Unknown | 15 (44%) |
| KRAS mutations, n (%) | |
| Positive | 0 (0%) |
| Negative | 19 (56%) |
| Unknown | 15 (44%) |
| History of smoking | 23 (68%) |
| History of brain metastases | 11 (32%) |
| ECOG performance status score, n (%) | |
| 0 | 2 (6%) |
| 1 | 31 (91%) |
| 2 | 1 (3%) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group